WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206220
CAS#: 905585-60-6
Description: AZD6918 is a novel potent and selective inhibitor of the Trk tyrosine kinases. AZD-6918 attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth.
MedKoo Cat#: 206220
Name: AZD-6918
CAS#: 905585-60-6
Chemical Formula: C20H20F2N6O
Exact Mass: 398.1667
Molecular Weight: 398.4178
Elemental Analysis: C, 60.29; H, 5.06; F, 9.54; N, 21.09; O, 4.02
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AZD-6918; AZD6918; AZD 6918.
IUPAC/Chemical Name: (S)-5-Fluoro-2-[[1-(4-fluorophenyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]nicotinonitrile
InChi Key: QRAQXWWNHQMCBH-LBPRGKRZSA-N
InChi Code: InChI=1S/C20H20F2N6O/c1-11(2)29-18-9-17(27-28-18)25-20-16(22)8-14(10-23)19(26-20)24-12(3)13-4-6-15(21)7-5-13/h4-9,11-12H,1-3H3,(H3,24,25,26,27,28)/t12-/m0/s1
SMILES Code: N#CC1=C(N[C@H](C2=CC=C(F)C=C2)C)N=C(NC3=NNC(OC(C)C)=C3)C(F)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 398.4178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ. Trk inhibitor attenuates the
BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and
in vivo. Cancer Biol Ther. 2015;16(3):477-83. doi: 10.1080/15384047.2015.1016659.
PubMed PMID: 25700942; PubMed Central PMCID: PMC4623105.
2: Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. Role and
relevance of TrkB mutations and expression in non-small cell lung cancer. Clin
Cancer Res. 2011 May 1;17(9):2638-45. doi: 10.1158/1078-0432.CCR-10-3034. PubMed
PMID: 21242122; PubMed Central PMCID: PMC3086954.
Phase I clinical trial for AZD-6918 was started in 2009. However, AZD6918 was discontinued from development due to an unacceptable pharmacokinetic profile. Drug was discontinued in 2009.
